Strong 10-year performance with 258.39% gain exceeding S&P 500 returns. Analysts expect continued upside supported by sustained instrument replacement demand, resilient pharma exposure, expanding specialty CDMO activity, and recent product launches. Stock jumped 8.07% in past four weeks with no downward earnings estimate revisions for fiscal 2026.
Mixed quarterly performance with Asia Pacific beating expectations (+3.15%) while Europe missed estimates (-3.24%). Overall revenue growth of 8.1% is solid, but the Zacks Rank #3 (Hold) rating and mixed regional performance suggest the stock should perform in line with the market rather than outperform. Recent stock price outperformance (11.2% vs 3.9% S&P 500) is noted but not reflected in analyst ratings.
Listed among key players in a market growing at 5.06% CAGR, with opportunities in cloud deployment and regulatory compliance solutions.
Identified as a major market player positioned to benefit from the 19% CAGR growth in the gRNA market through 2034
Invested $479 million in R&D in 2024, actively positioning for AI-integrated bioinformatics workflows and maintaining competitive positioning in life sciences instrumentation.
Identified as a major player in the expanding laboratory equipment services market with strong growth prospects driven by pharmaceutical innovation and diagnostic facility expansion.
Identified as a major player in the automated liquid handling systems market, which is experiencing robust growth driven by pharmaceutical and biotech R&D expansion.
Shares surged over 18% after first-quarter results beat Wall Street estimates with revenue of $1.84 billion versus estimated $1.80 billion. Strong short and medium-term price trends.
Company beat analyst estimates on both revenue and earnings per share, demonstrated broad-based growth across all three business segments, and raised full-year 2026 guidance for both revenue and adjusted net income, indicating strong operational momentum and management confidence.
Identified as a leading company in the market and received European regulatory approval for its SurePrint G3 Human CNV Microarray in May 2025, indicating successful product expansion and market penetration.
The acquisition of Biocare Medical is a strategic move expected to enhance revenue growth, margins, and EPS accretion. Biocare's strong double-digit growth since 2021 and 300+ specialized antibodies strengthen Agilent's market position in the high-growth IHC market. However, positive sentiment is tempered by the stock's recent underperformance and weak momentum indicators.
Listed among key market players in the expanding microplate systems sector, which is experiencing robust growth due to rising demand for high-throughput screening and advanced analytical capabilities.
Articles that tag A but are mainly about other companies.
Listed as a leading metabolomics company providing chromatography, spectroscopy, and laboratory services for metabolite profiling and precision medicine, positioned to benefit from market growth.
Listed among key players in a growing market driven by genomics expansion and high-throughput research platform adoption.
Identified as a principal competitor in the multiplex assays market, well-positioned to capture growth from laboratory automation and expanding companion-diagnostic requirements.
Introduced next-generation triple quadrupole LC-MS/MS system in November 2024 optimized for clinical laboratory applications, positioning the company to capture growth in high-throughput clinical diagnostics.
Listed among key market players benefiting from growth in cancer biomarker profiling technologies and increased adoption of precision medicine approaches.
Launched Agilent Advanced Therapeutics in 2026, integrating BIOVECTRA and Nucleic Acid Solutions, strengthening regional position in North America's oligonucleotide CDMO market.
Listed as a leading player in a market experiencing sustained growth from molecular diagnostics and genomics research expansion.
Identified as a key company in the oxidative stress assay market, positioned to benefit from rising demand for advanced biomarker diagnostics and pharmaceutical research applications.
Identified as a major company in the LIMS market, benefiting from strong market growth and increasing demand for laboratory informatics solutions.
Stock jumped 17% after fiscal Q2 revenue and non-GAAP EPS beat estimates with management raising revenue guidance.
Included as a major competitor in the expanding tissue diagnostics market. Benefits from growing adoption of precision medicine and digital pathology technologies.
As a major NGS market player, Agilent benefits from rising demand for targeted sequencing, custom panels, and improvements in sequencing chemistries driving the consumables segment.
Acquiring Biocare Medical for $950 million to expand its life sciences and diagnostics capabilities.
Included among major companies in molecular diagnostics market. Positioned to benefit from technological innovations in diagnostic platforms and sequencing technologies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
